NasdaqGS - Nasdaq Real Time Price USD
Enanta Pharmaceuticals, Inc. (ENTA)
13.90 -0.16 (-1.14%)
As of 11:32:23 AM EDT. Market Open.
Trade ENTA on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for ENTA
- Previous Close
14.06 - Open
14.08 - Bid 10.34 x 200
- Ask 17.83 x 200
- Day's Range
13.90 - 14.64 - 52 Week Range
6.43 - 17.15 - Volume
120,370 - Avg. Volume
177,148 - Market Cap (intraday)
404.189M - Beta (5Y Monthly) 0.99
- PE Ratio (TTM)
-- - EPS (TTM)
-2.60 - Earnings Date (est.) Aug 10, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
20.14
Recent News
View More
Performance Overview
Trailing total returns as of 6/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
ENTA
11.86%
S&P 500 (^GSPC)
8.41%
1-Year Return
ENTA
89.89%
S&P 500 (^GSPC)
21.82%
3-Year Return
ENTA
37.50%
S&P 500 (^GSPC)
70.67%
5-Year Return
ENTA
71.13%
S&P 500 (^GSPC)
73.95%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/23/2026
Market Cap
409.13M
Enterprise Value
301.89M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.11
Price/Book (mrq)
3.51
Enterprise Value/Revenue
4.36
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-89.56%
Return on Assets (ttm)
-11.84%
Return on Equity (ttm)
-59.00%
Revenue (ttm)
69.21M
Net Income Avi to Common (ttm)
-61.98M
Diluted EPS (ttm)
-2.60
Balance Sheet and Cash Flow
Total Cash (mrq)
163.77M
Total Debt/Equity (mrq)
160.07%
Levered Free Cash Flow (ttm)
7.69M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreDaily – Vickers Top Buyers & Sellers for 02/13/2025
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Lowering target price to $10.00
ENANTA PHARMACEUTICALS INC has an Investment Rating of SELL; a target price of $10.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetWhat does Argus have to say about ENTA?
ENANTA PHARMACEUTICALS INC has an Investment Rating of SELL; a target price of $12.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetWhat does Argus have to say about ENTA?
ENANTA PHARMACEUTICALS INC has an Investment Rating of SELL; a target price of $12.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice Target